trial

Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium

NCTId NCT02831231
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 70 (actual)
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Primary completion 2016-10-28
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
70 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2016-09-07
Primary completion
2016-10-28
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

Karuna Therapeutics, Inc., a Bristol Myers Squibb companyLead Sponsor

Investigators

1
Lukasz Biernat, PhDPrincipal Investigator

Sites

1 total
Cincinnati, United States

Facts & assertions

4 sourced
Enrollment
70
Phase
PHASE1
Primary Completion Date
2016-10-28
Status
COMPLETED
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Lukasz Biernat, PhD
person